Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials
Velavigo, a Shanghai-based pharmaceutical startup, has reportedly secured USD 60 million in a Pre-A+ financing...
Matchpoint Therapeutics Partners with Novartis to Develop Oral Covalent Inhibitors for Inflammatory Diseases
Matchpoint Therapeutics, a privately held biotechnology company based in Watertown, Massachusetts, announced an exclusive option...
SinoCellTech’s SCT640C Injection Receives NMPA Approval for RA Clinical Trials
China-based SinoCellTech Group Ltd (SHA: 688520) announced today that its self-developed product, SCT640C injection, has...
Hengrui Pharmaceuticals’ HRS8179 and HRS-1893 Receive NMPA Clinical Trial Approval
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced today that it has received clinical...
Cryofocus Medtech’s Asthma Cryoablation System Granted FDA Breakthrough Device Designation
China-based Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) announced today that its self-developed asthma cryoablation...
3Sbio and Pfizer Finalize Licensing Agreement for PD-1/VEGF Bispecific Antibody SSGJ-707
China-based 3Sbio Inc. (HKG: 1530) announced today that its global licensing agreement with Pfizer Inc.,...
Roche AG Reports 7% Sales Growth in H1 2025, Driven by Pharmaceuticals Expansion
Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced its H1 2025 financial results, reporting...
GenFleet Therapeutics Announces Fast Track Designation for GFH375/VS-7375 in Pancreatic Cancer
China-based GenFleet Therapeutics announced on July 25, 2025, that its oral KRAS G12D inhibitor, GFH375/VS-7375,...
Leads Biolabs Lists on Hong Kong Stock Exchange in $189 Million IPO
China-based Leads Biolabs (HKG: 9887) officially listed on the Main Board of the Hong Kong...
Everest Medicines Completes HK$1.57 Billion Share Placement to Advance R&D and Commercialization
China-based Everest Medicines (HKG: 1952) announced today the completion of a share placement of 22,561,000...
Yangtze River Pharmaceutical’s Tadalafil Hydrochloride Tablets Approved for ED Treatment in China
China-based Yangtze River Pharmaceutical Group announced on July 25, 2025, that its Class 1 innovative...
Ipsen’s Cabometyx Approved by European Commission for Neuroendocrine Tumors
France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced that its anticancer drug Cabometyx...
NHSA Announces Reforms to Centralized Drug Procurement Policies Beyond Lowest Price
The National Healthcare Security Administration (NHSA) held a press conference today on the “High-Quality Completion...
Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025
Boehringer Ingelheim announced today its financial results for the first half of 2025, reporting group...
Kelun-Biotech’s SKB378/WIN378 Enters Global Phase II Trial for Asthma Treatment
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced on July 23, 2025, that its partner...
Sirius Therapeutics’ SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases
China-based Sirius Therapeutics announced on July 23, 2025, that its next-generation siRNA therapy, SRSD107, has...
Akeso Enrolls First Patient in Phase III Trial of Ivonescimab for Pancreatic Cancer
China-based Akeso Biopharma (HKG: 9926) announced on July 24, 2025, that the first patient has...
Youcare Pharma’s YKYY029 Receives FDA IND Approval for Hypertension Treatment
China-based Youcare Pharmaceutical Group (SHA: 688658) announced on July 24, 2025, that its subsidiary, Beijing...
National Health Commission Launches Integrated Medical and Elder Care Demonstration Projects
On July 22, 2025, China’s National Health Commission (NHC) issued the “Work Plan for Integrated...
Kintor’s KX-826 Topical Solution Meets Primary Endpoint in AGA Phase II Trial
China-based Kintor Pharmaceutical (HKG: 9939) announced on July 24, 2025, that its self-developed 1.0% KX-826...